LeMaitre Vascular Inc (LeMaitre Vascular) provides medical devices and human tissue cryopreservation services that are used in treatment of peripheral vascular diseases. It develops, manufactures, and markets disposable and implantable devices used by vascular surgeons in open vascular surgeries and minimally invasive procedures. Its products are also used by cardiac surgeons and neurosurgeons.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focus on the development of cardiac allograft and next-generation powered phlebectomy projects and enhancement of existing product lines. The company launched the PhasTIPP Powered Phlebectomy System in the US in the first half of 2024. Manufacturing transfers have become a significant portion of the company's R&D spend, with the completion of the CardioCel and VascuCel transfer to Burlington in 2024. The company has also been working on obtaining MDR CE marks for its products, receiving several in 2024 and expecting to receive a total of 23 by the end of 2025. Additionally, the company has invested in allograft preservation services, constructing a new cleanroom in 2024 to support tissue distribution in Germany and pursuing approvals in Ireland in 2025. The company has also increased its focus on clinical trials due to rising regulatory requirements, with efforts to obtain approval for the XenoSure patch in China, receiving cardiac indication approval in December 2024. The company maintains a limited portfolio of patents in the US, with issued patents set to expire through 2031. It maintains and licenses patents in the US, Europe, and other locations related to several aspects of certain of its products and manufacturing processes. In FY2024, the company invested US$15.6 million on its R&D activities, which as a percentage of revenue stood at 7.1%.